International uniform response criteria for multiple myeloma

被引：2217

作者：

Durie, B. G. M.

Harousseau, J-L

Miguel, J. S.

Blade, J.

Barlogie, B.

Anderson, K.

Gertz, M.

Dimopoulos, M.

Westin, J.

Sonneveld, P.

Ludwig, H.

Gahrton, G.

Beksac, M.

Crowley, J.

Belch, A.

Boccadaro, M.

Turesson, I.

Joshua, D.

Vesole, D.

Kyle, R.

Alexanian, R.

Tricot, G.

Attal, M.

Merlini, G.

Powles, R.

Richardson, P.

Shimizu, K.

Tosi, P.

Morgan, G.

Rajkumar, S. V.

机构：

[1] Aptium Oncol Inc, Cedars Sinai Outpatient Canc Ctr, Los Angeles, CA 90048 USA

[2] Inst Biol, Nantes, France

[3] Univ Salamanca, E-37008 Salamanca, Spain

[4] Hosp Clin Barcelona, Barcelona, Spain

[5] MIRT UAMS, Little Rock, AR USA

[6] DFCI, Boston, MA USA

[7] Mayo Clin, Rochester, MN USA

[8] Alexandra Hosp, Athens, Greece

[9] Gothenburg Univ, S-41124 Gothenburg, Sweden

[10] Univ Gothenburg, Rotterdam, Netherlands

[11] Wilhelminenspital Stat Wien, Vienna, Austria

[12] Karolinska Inst, S-10401 Stockholm, Sweden

[13] Ankara Univ, TR-06100 Ankara, Turkey

[14] Canc Res & Biostat, Seattle, WA USA

[15] Univ Turin, I-10124 Turin, Italy

[16] Univ Malmo, Malmo, Sweden

[17] Royal Prince Alfred Hosp, Sydney, NSW, Australia

[18] St Vincents Comprehens Canc Ctr, New York, NY USA

[19] MD Anderson, Houston, TX USA

[20] Purpan Hosp, Toulouse, France

[21] Univ Pavia, I-27100 Pavia, Italy

[22] Dana Farber Canc Inst, Boston, MA 02115 USA

[23] Nagoya City Midori Gen Hosp, Nagoya, Aichi, Japan

[24] Univ Bologna, I-40126 Bologna, Italy

[25] Royal Marsden Hosp, London SW3 6JJ, England

来源：

LEUKEMIA | 2006年 / 20卷 / 09期

关键词：

myeloma; response criteria; staging; survival duration; uniform criteria; clinical outcomes;

D O I：

10.1038/sj.leu.2404284

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

New uniform response criteria are required to adequately assess clinical outcomes in myeloma. The European Group for Blood and Bone Marrow Transplant/International Bone Marrow Transplant Registry criteria have been expanded, clarified and updated to provide a new comprehensive evaluation system. Categories for stringent complete response and very good partial response are added. The serum free light-chain assay is included to allow evaluation of patients with oligo-secretory disease. Inconsistencies in prior criteria are clarified making confirmation of response and disease progression easier to perform. Emphasis is placed upon time to event and duration of response as critical end points. The requirements necessary to use overall survival duration as the ultimate end point are discussed. It is anticipated that the International Response Criteria for multiple myeloma will be widely used in future clinical trials of myeloma.

引用

页码：1467 / 1473

页数：7

共 28 条

[1] Graft outcome - Impact of complete remission with intensive therapy in patients with responsive multiple myeloma [J].

Alexanian, R ;

Weber, D ;

Giralt, S ;

Dimopoulos, M ;

Delasalle, K ;

Smith, T ;

Champlin, R .

BONE MARROW TRANSPLANTATION, 2001, 27 (10) :1037-1043

[2] Single versus double autologous stem-cell transplantation for multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Facon, T ;

Guilhot, F ;

Doyen, C ;

Fuzibet, JG ;

Monconduit, M ;

Hulin, C ;

Caillot, D ;

Bouabdallah, R ;

Voillat, L ;

Sotto, JJ ;

Grosbois, B ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (26) :2495-2502

[3] Thalidomide and hematopoietic-cell transplantation for multiple myeloma [J].

Barlogie, B ;

Tricot, G ;

Anaissie, E ;

Shaughnessy, J ;

Rasmussen, E ;

van Rhee, F ;

Fassas, A ;

Zangari, M ;

Hollmig, K ;

Pineda-Roman, M ;

Lee, C ;

Talamo, G ;

Thertulien, R ;

Kiwan, E ;

Krishna, S ;

Fox, M ;

Crowley, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (10) :1021-1030

[4] Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US intergroup trial S9321 [J].

Barlogie, B ;

Kyle, RA ;

Anderson, KC ;

Greipp, PR ;

Lazarus, HM ;

Hurd, DD ;

McCoy, J ;

Dakhil, SR ;

Lanier, KS ;

Chapman, RA ;

Cromer, JN ;

Salmon, SE ;

Durie, B ;

Crowley, JC .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :929-936

[5]

Blade Joan, 1998, British Journal of Haematology, V102, P1115, DOI 10.1046/j.1365-2141.1998.00930.x

[6] Serum test for assessment of patients with Bence Jones myeloma [J].

Bradwell, AR ;

Carr-Smith, HD ;

Mead, GP ;

Harvey, TC ;

Drayson, MT .

LANCET, 2003, 361 (9356) :489-491

[7] Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma [J].

Cavo, M ;

Zamagni, E ;

Tosi, P ;

Tacchetti, P ;

Cellini, C ;

Cangini, D ;

de Vivo, A ;

Testoni, N ;

Nicci, C ;

Terragna, C ;

Grafone, T ;

Perrone, G ;

Ceccolini, M ;

Tura, S ;

Baccarani, M .

BLOOD, 2005, 106 (01) :35-39

[8] High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma [J].

Child, JA ;

Morgan, GJ ;

Davies, FE ;

Owen, RG ;

Bell, SE ;

Hawkins, K ;

Brown, J ;

Drayson, MT ;

Selby, PJ .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (19) :1875-1883

[9] POEMS syndrome: definitions and long-term outcome [J].

Dispenzieri, A ;

Kyle, RA ;

Lacy, MQ ;

Rajkumar, SV ;

Therneau, TM ;

Larson, DR ;

Greipp, PR ;

Witzig, TE ;

Basu, R ;

Suarez, GA ;

Fonseca, R ;

Lust, JA ;

Gertz, MA .

BLOOD, 2003, 101 (07) :2496-2506

[10] Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma [J].

Drayson, M ;

Tang, LX ;

Drew, R ;

Mead, GP ;

Carr-Smith, H ;

Bradwell, AR .

BLOOD, 2001, 97 (09) :2900-2902

← 1 2 3 →